Structure Therapeutics
Latest round
- Series B
Last raised
- Aug 2022
Total raised
- $191M
Investors
- 21
About Structure Therapeutics
, operates as a biotechnology company that develops medicines for patients with chronic diseases, including cardiovascular, metabolic, and pulmonary conditions. The company's CEO Dr. Stevens has been involved in the discovery and development of several therapeutic molecules including Palnziq, which was developed at BioMarin Pharmaceutical and approved in 2018 to treat phenylketonuria. He also founded Receptos which developed Zeposia—a GPCR agonist targeting the S1PR1 receptor approved in 2020 for multiple sclerosis and 2021 for ulcerative colitis. In February 2023, Structure Therapeutics Inc.1 million in an IPO at USD 15 per share on the Nasdaq under the ticker symbol "GPCR". The company focuses on G-protein coupled receptors (GPCRs). Its platform enables the conversion of biologics and peptide therapeutics into orally available small molecule drugs with enhanced pharmaceutical properties, including improved bioavailability and stability. Using artificial intelligence, machine learning, and other techniques, the company designs small molecules intended to address validated targets of biologic drugs.
Who invested in Structure Therapeutics
21 investors across 4 rounds
See all investors in Structure Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Structure Therapeutics
Who invested in Structure Therapeutics?
Structure Therapeutics has 21 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Structure Therapeutics raised?
Structure Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Structure Therapeutics last raise money?
Structure Therapeutics's most recent round on record is a Series B, in Aug 2022.
What does Structure Therapeutics do?
, operates as a biotechnology company that develops medicines for patients with chronic diseases, including cardiovascular, metabolic, and pulmonary conditions.
Where is Structure Therapeutics headquartered?
Structure Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Structure Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Structure Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Structure Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.